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Purpose: Although safe at therapeutic levels, excess intake of acetaminophen can lead to hepatic injury or acute
liver failure (ALF). A number of different factors influence metabolism and hepatotoxicity of acetaminophen in
patients. Three of the most important are a patient’s physiological response to fasting, alcohol consumption, and
chronic acetaminophen consumption. The molecular and enzymatic underpinnings for these processes have been
extensively studied. The purpose of this study is to examine and quantify the effects of the noted conditions,
provide possible reasons for conflicting clinical observations, and examine dangers associated with uptake of
therapeutic doses of acetaminophen.
Methods: In order to gain a better understanding of the transient hepatic changes associated with each
physiological and nutritional process, examine risks of ALF associated with individuals based on their unique
lifestyle and health issues, and predict improved dosing strategies, a multi-compartmented physiologically-based
pharmacokinetic (PBPK) model of acetaminophen metabolism in adult humans was developed. By varying the
parameters of this model, changes in metabolism of acetaminophen and its toxic byproducts for a variety of
medically relevant conditions were assessed.
Results: Simulated results indicate that in case of chronic ingestion of acetaminophen, the increased rate of
glucuronidation plays a significant role in protecting patients from liver damage following uptake of excessive
quantities. Analysis of metabolism of acetaminophen in persons who have imbibed excessive amounts of alcohol
show that the primary reason for hepatotoxicity in such individuals is decreased availability of glutathione in the
liver and not the observed increased production of toxic byproducts. When the glutathione depleting effects of
alcohol consumption are combined with those associated with chronic acetaminophen use, intake of slightly
higher quantities than the recommended therapeutic doses of acetaminophen can result in initiation of
hepatotoxicity.
Conclusions: The results of simulations show that, in healthy and well-fed individuals, chronic uptake of
acetaminophen doses even five times the therapeutic recommendations should be safe. However, in persons who
have diminished hepatic glutathione regeneration capacities, depending on the magnitude of this deleterious
shortcoming, minor overdoses can result in hepatotoxicity. Hence, it can be concluded that for such persons,
acetaminophen is just as toxic as any other compound that would generate reactive oxidative species.
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Acetaminophen (a.k.a. paracetamol, acetyl-para-aminophenol)
(APAP) is a popular over-the-counter analgesic and
antipyretic drug. By one estimate, 36% of Americans use at
least one tablet of APAP per month (Gregory et al., 2010);
and in the United Kingdom an average of 55 tablets per
person are consumed each year (Jones, 1998).
At therapeutic levels, acetaminophen is generally safe for
humans (Thomas, 1993); however, over self-medication (for
therapeutic or suicidal intentions) or excess prescription of
APAP due to incorrect assessment of risks to patients with
unique physiological determinants (McQuade et al., 2012)
can result in acetaminophen poisoning, dose-dependent
hepatotoxicity, and possibly ALF. Unfortunately, ALF is a
common outcome. APAP poisoning is the leading cause
of ALF in the United States (Schiødt et al., 2003; Nourjah
et al., 2006) and some European countries (Larsen et al.,
1995; Bernal, 2003).
The hepatotoxic agent in these cases is a byproduct of
APAP metabolism. As part of phase II drug metabolism,
the bulk fraction of APAP is glucuronidated (APAP-G)
and sulfated (APAP-S) to form conjugates that are more
water-soluble than APAP. These compounds are primarily
excreted through urine (Bessems and Vermeulen, 2001).
Approximately 55 and 30 percent of the administered drug
is excreted via urine as APAP-G and APAP-S respectively
(Howie et al., 1977).
However, during phase I metabolism, a small fraction
of APAP (~5-15%) is oxidized by liver microsomal
cytochrome P-450 s (CYP) to form a toxic byproduct
N-acetyl-p-benzoquinone imine (NAPQI). The cytochromes
involved in oxidation of APAP are CYP2E1 (Raucy et al.,
1989; Lee et al., 1996), CYP3A4 (Thummel et al., 1993),
CYP2D6 (Dong et al., 2000), CYP1A2 (Raucy et al., 1989),
and CYP2A6 (Chen et al., 1998). CYP2E1 is the primary
enzyme catalyzing the production of NAPQI at lower
APAP concentrations. In CYP2E1 mutant mice, the animals
display much greater tolerance to APAP than wild type ani-
mals, and only at high concentrations (>600 mg/kg) do they
display signs of significant toxicity (Lee et al., 1996). NAPQI
produced as a result of uptake of a normal dose of APAP is
rapidly detoxified through conjugation with molecules of
the glutathione (GSH) antioxidant. However, if the store of
GSH in the liver dips below 30-20% of its normal value,
NAPQI will begin to accumulate, bind to various liver
proteins, and cause liver damage (Mitchell et al., 1973).
A number of different factors influence metabolism and
hepatotoxicity of APAP in patients. These include age
(Miller et al., 1976), genetics (Ueshima et al., 2006),
concurrent uptake of other drugs (Toes et al., 2005),
viral infections (Barbaro et al., 1996; Moling et al.,
2006), alcohol use (Schiødt et al., 2002), fasting/starvation
(Whitcomb and Block, 1994), and tobacco use (Schmidt
and Dalhoff, 2003).This manuscript reports the development and utilization
of a multi-compartmented physiologically-based pharmaco-
kinetic (PBPK) model of APAP metabolism in average adult
humans to predict the time-course of changes in liver GSH
levels following fasting, chronic APAP use, and alcohol
consumption. Model simulations have been used to quan-
tify the enhancing or reducing influence of each of the
above noted lifestyle choices on the possibility of inducing
hepatotoxicity following use of APAP.
Methods
Whole-body PBPK models provide a framework for inte-
grating and interpreting data from disparate sources in
order to predict the time-course of xenobiotic metab-
olism. PBPK models dynamically simulate outcome of
metabolism of various therapeutic and/or toxic com-
pounds on the basis of their structure and other im-
portant physiological input parameters such as tissue
volumes, organ composition, blood flow rate, and system-
level clearance rates. Thus, PBPK models are ideal tools
for assessing toxicological risks early in the drug devel-
opment pipeline (Clark et al., 2004).
Mathematical formulation
In the majority of PBPK models, the mammalian body is
treated as a series of well stirred homogenous compart-
ments that are connected to one another via arterial and
venous blood flow. The rates of biochemical processes,
including metabolism, are modeled at different levels of
detail depending on the quality and availability of various
kinetic and physiological parameters.
In most PBPK models, the transient change in each


















where Cαi tð Þ denotes the concentration of compound i
in compartment α; Cai
b tð Þ represents the concentration
of the compound i in the arterial blood; Vα is the volume
of compartment α; Qα is the blood flow into compartment
α; Y αi and Z
α
i are the amounts of drug i that are directly
imported and removed from compartment α, respectively.
Pα:plasmai and BP are the tissue plasma partition coefficient
and blood to plasma ratio respectively. Blood, skin, gut,
and lung are the primary routes of introducing com-
pounds into a system and hence might have a non-zero
value for the term dY
α
i tð Þ
dt . Introduction of a compound into
Figure 1 Schematic representation of the PBPK model
structure. Blue compartments are the eliminating organs.
Table 1 Physiological parameters
Organ Volume Blood flow Partition coefficients
α Vα (ml) Qα (ml/min) Pα:plasmaAPAP
Adipose 8372 325 0.312
Bone 5992 325 0.682
Brain 1400 780 1.05
Gut 1197 1105 0.92
Heart 329 260 0.852
Kidney 308 1235 0.906
Liver 1799 1625 0.93
Lung 532 6500 0.87
Muscle 28000 1105 0.88
Rest of body 13895 520 1
Skin 2597 325 0.853




Organ volume and blood flow values are from (Luttringer et al., 2003). The
partition coefficients were calculated using the formula from Poulin and
coworkers (Poulin and Theil, 2000; Poulin et al., 2001).
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by the Dirac delta function such that:
dY αi tð Þ
dt
¼ Dδ tð Þ ð2Þ
where D denotes the dose. For single uptakes δ(t) = 1 at
t = t0 and zero at all other times. For regular periodic up-
takes: δ(t) = 1 at t = nT, where n is an integer (n = 0,1,2…)
and T is the time interval between uptakes; δ(t) = 0 at all
other times.
For non-eliminating tissues dZ
α
i tð Þ
dt ¼ 0. In the eliminating




on the mode of elimination. If a compound is metabolized
then the simplest formulations would involve introduction
of first order kinetics such that:
dZαi tð Þ
dt
¼ kαi Cαi tð Þ ð3Þ









In equation 3 the drug is metabolized at a rate dependent
on the concentration of drug in the tissue and a constant,
k. In equation 4, a fraction of the drug (E < 1) that is enter-
ing the tissue is extracted (Poulin and Theil, 2002b). For
cases where one would need to account for affinity of a








Km;i;j þ Cαi tð Þ
ð5Þ
where Km,i,j represents the Michaelis-Menten coefficient for
interaction of drug i with enzyme j, n denotes the number
of enzymes in compartment α that can catalyze breakdown
of drug i, and Vmax,i,j represents the maximum rate of me-
tabolism of drug i by enzyme j.
Normal APAP metabolism
A 14-compartment model of human physiology (see
Figure 1), where the various tissues are connected by
the blood circulatory system, was developed. The collection
of ODEs that make up the model was solved by using the
Mathematica suite of programs (version 9.0, Wolfram
Research Inc., Champaign, IL). The non-drug specific
system parameters are from (Luttringer et al., 2003)
(see Table 1). The tissue-specific APAP partition coefficients
were calculated using the formula proposed by Poulin and
coworkers (Poulin and Theil, 2000; Poulin et al., 2001). The
BP value for APAP was set to one (Poulin and Theil, 2002a).
The model contains two eliminating tissues, liver and
kidney. To model APAP metabolism and excretion,equation 4 is used to account for non-enzymatic export of
compounds (kidney), and equation 5 accounts for the
enzymatic breakdown (liver) of the drug. In the model
the latter formulation accounts for three enzymatic pro-
cesses, APAP glucuronidation, sulfation, and oxidation;
the last results in formation of NAPQI. The kinetic param-
eters for the glucuronidation and sulfation reactions are
from (Reith et al., 2009). The average person was assumed
to weigh 70 kg. The Vmax value for the oxidation reaction is
based on measurements from (Mitchell et al., 1973). For
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2007). Studies have shown the bioavailability of APAP
after consuming pills is about 79% (Ameer et al., 1983);
thus, for cases when APAP is taken orally, we used this
value for our simulations.
GSH metabolism
For simulations of CliverGSH tð Þ, we use the equation:
dCliverGSH tð Þ
dt
¼ FliverGSH  CliverGSH 0ð Þ−CliverGSH tð Þ
  
−kII
 CliverGSH tð Þ  CliverNAPQI tð Þ ð6Þ
where kII is the bimolecular interaction constant for
NAPQI and GSH. FliverGSH represents a coefficient for pro-
duction GSH in the liver. Synthesis of GSH in the liver
has been extensively examined, and a number of differ-
ent factors that regulate normal and stressed production
of GSH have been studied (Griffith, 1999; Lu, 1999; Wu
et al., 2004). However, these kinetic alterations have not
been fully quantified. This formulation for generation of
GSH is similar to those incorporated in other models
(Chen and Gillette, 1988). It does not permit CliverGSH tð Þ
to exceed the normal concentration of GSH in the liver
CliverGSH 0ð Þ
 
, and the rate of regeneration is directly propor-
tional to depletion of GSH levels. The value of FliverGSH was
optimized so that a single uptake of APAP greater than
15 g would result in greater than 70% depletion of liver
GSH pool and initiate hepatic damage (Rumack, 2002).
Although it has been shown that concentration (Smith
et al., 1979) and rates of metabolism of GSH vary in differ-
ent regions of the liver (Kera et al., 1988; Penttilä, 1990),
this level of detail has not been incorporated into the
model, and as noted earlier, the liver is assumed to be a
well-mixed single compartment.
Modeling chronic APAP uptake
When modeling chronic uptake of APAP, uptake of vari-
ous doses were simulated at regular 6-hour intervals.
Experiments have shown that chronic uptake of APAP
alters the routes of APAP metabolism. Due to cofactor
depletion, clearance via sulfate formation is lowered,
while clearance through glucuronidation is increased
(Hendrix-Treacy et al., 1986; Gelotte et al., 2007). Since
liver concentrations of UDP-glucuronosyltransferase or
sulfation cofactors are not explicitly solved in the model,
this phenomenon was modeled by multiplying the Vmax
for the glucuronidation and sulfation by coefficients Cog
and Cos, respectively. This results in modification of the
overall clearance via APAP-G and APAP-S production.
The experimentally measured changes in routes of clear-
ance (Gelotte et al., 2007) were used to calculate the
maximum values of Cog and Cos. Since the time courseof induction of UDP-glucuronosyltransferase and depletion
of sulfate stores in liver are not well understood and differ
based on diet and numerous other factors, the value of Cog














 δ tð Þ ð8Þ
Cog = Cos = 1 and δ(t) = 1 when t ≤ 4320 minutes and
δ(t) = 0 when t > 4320. Thus, in the simulations the
time course for observed changes in metabolism of APAP is
3 days (4320 minutes). This length of time matches the first
time point for which changes in routes of APAP metabol-
ism were observed experimentally (Gelotte et al., 2007).
The values for Comaxg and Co
max
s for different doses of
APAP are reported in Table 2.
Experimental data show that diversion of APAP to glu-
curonidation increases as the dose increases from 1 g to
2 g every 6 hours (Gelotte et al., 2007), but it is not clear if
the pattern holds for higher doses. Because of this uncer-
tainty, for chronic ingestion of doses greater than 2 g, levels
of induction similar to that of 2 g doses were used.
Effects of alcohol on APAP metabolism
Alcohol ingestion stimulates production of NAPQI
through induction of CYP2E1 enzyme and this effect
can last up to 5 days in humans after drinking has stopped
(Perrot et al., 1989; Takahashi et al., 1993). For simulations
of APAP metabolism after drinking alcohol, results from a
study (Thummel et al., 2000) that found excessive alcohol
consumption (continual blood alcohol concentration of
3 g/L for 200 hours, similar to consuming nearly 14 Liters
of 80 proof spirits in less than 9 days) increases CYP2E1
concentration by a factor of 2.14 were used. For simula-
tions of APAP metabolism in alcoholics or binge drinkers,
the maximum enhancement in the activity of the CYP2E1
was assumed. Hence, the normal Vmax for the NAPQI
production was multiplied by the above noted value
ComaxEtOH ¼ 2:14
 
. Half-life for recovery of CYP2E1 activity
after alcohol ingestion is about 60 hours (Imai et al., 2011).
As with changes associated with chronic APAP use, the








 δ tð Þ ð9Þ
and δ(t) = 1 when t ≤ 7200 minutes and δ(t) = 0 when
t > 7200.
Chronic alcoholics also have significantly lower concen-
trations of hepatic GSH (Lauterburg and Velez, 1988). A
number of different causes have been proposed. These
include reduced rates of GSH production (Lauterburg
Table 2 Kinetic parameters of the model
Parameter Value Units Reference
Comaxg (1 g/6 hrs) 1.5 (Gelotte et al., 2007)
Comaxg (2 g/6 hrs) 2.25 (Gelotte et al., 2007)
Comaxs (1 g/6 hrs) 0.5 (Gelotte et al., 2007)
Comaxs (2 g/6 hrs) 0.3 (Gelotte et al., 2007)
ComaxEtOH−CYP 2.14 (Thummel et al., 2000)
ComaxEtOH−GSH 0.5 (Lauterburg and Velez, 1988)




6 ml/(mmol min) (Coles et al., 1988)
Kglucuronidationm 6.89 mmol/L (Reith et al., 2009)
Ksulfationm 0.097 mmol/L (Reith et al., 2009)
KCYPm 0.28 mmol/L (Reith et al., 2009)
Vglucuronidationmax 0.97 mmol/(hr kg) (Reith et al., 2009)
Vsulfationmax 0.011 mmol/(hr kg) (Reith et al., 2009)
VCYPmax 0.035 mmol/(hr kg) (Mitchell et al., 1973)
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(Fernandez-Checa et al., 1989; Choi et al., 2000), re-
duced cysteine production and its diversion to produce
taurine (Kim et al., 2003), and increased lipid peroxida-
tive damage resulting from formation of acetaldehyde
(Vina et al., 1980). For simulations of APAP metabolism in
alcoholics the starting value of steady state hepatic GSH
concentration were halved ( Calcoholic liverGSH 0ð Þ ¼ CliverGSH 0ð Þ=2
 
(Lauterburg and Velez, 1988; Choi et al., 2000). It has been
shown that soon after persons stop consuming alcohol
(24 hours, (Choi et al., 2000)), levels of hepatic GSH start
to return to normal. Accordingly, when accounting for
the alcohol induced reduction of GSH production and
increased efflux from the liver, the rate of hepatic GSH
replenishment was augmented in a time dependent manner









 δ tð Þ ð10Þ
where δ(t) = 1 when t ≤ 1440 minutes and δ(t) = 0 when
t > 1440.
Effects of fasting on APAP metabolism
When modeling effects of fasting on acetaminophen
hepatotoxicity, it is important to account for the fact
that hepatic carbohydrate reserves are lower during
fasting, and this can result in a significant reduction in
rate of APAP glucuronidation (Price et al., 1987; Price and
Jollow, 1988; Price and Jollow, 1989). Fasting in rats results
in 40% reduction of glucuronidation and 30% reduction in
rate of sulfation of APAP (Price and Jollow, 1989). Extreme
fasting and uncontrolled diabetes can also result instabilization of CYP2E1 mRNA (Gonzalez et al., 1991). In
rats, CYP2E1 is induced by approximately 30-60% after
24 hr fasting (Hong et al., 1987; Johansson et al., 1988). For
simulations of fasting in humans, it was assumed that levels
of reduction of APAP-G and APAP-S production are similar
to those in rats Comaxg−fasting ¼ 0:6

and Comaxs−fasting ¼ 0:7Þ . It
was also assumed that in fasting individuals the activity of
oxidation reactions increases by 50% ComaxCYP−fasting ¼ 1:5
 
.
Fasting also reduces the ratio of liver to whole body
weight by approximately 20% in fasting rats (Price et al.,
1987). Although fasting might reduce the size of human
liver, our fasting simulations do not account for this
phenomenon and the liver volume remains constant for
malnourished and fasting individuals.
Fasting reduces the total GSH quantity in the liver due
to a reduced rate of GSH production. For the simulation
of acetaminophen metabolism in malnourished/fasting
persons, the initial hepatic concentration of GSH was
reduced by 25% Cfasting liverGSH 0ð Þ ¼ 34CliverGSH 0ð Þ
 
. This value is
based on measurements of GSH levels in malnourished
patients (Shi et al., 1982) and agrees with similar GSH
reductions in mice (~20%) (Price et al., 1987). Absence
of nutrients also reduces the rate of GSH regeneration,
and accordingly, we reduced the value for the starvation
simulations Ffasting liverGSH ¼ 34 FliverGSH
 
.
Metabolism in alcoholic, chronic APAP users
Table 3 shows that the effects of the examined nutritional
and lifestyle habits on different aspects of APAP me-
tabolism in liver can be complementary or conflicting.
Table 3 Effects of different dietary and lifestyle factors on various components of APAP and NAPQI metabolism
Habit Glucuronidation Sulfation Oxidation GSH metabolism
Chronic APAP use ⬆ ⬇ ⃠ ⃠
Alcohol consumption ⃠ ⃠ ⬆ ⬇
Fasting/Malnutrition ⬇ ⬇ ⬆ ⬇
(⬆) Increased activity, (⬇) decreased activity, (⃠) no effect. The reported behaviors have been gleaned from literature (chronic APAP use (Hendrix-Treacy et al.,
1986; Gelotte et al., 2007), alcohol consumption (Lauterburg et al., 1984; Fernandez-Checa et al., 1989; Perrot et al., 1989; Takahashi et al., 1993; Choi et al., 2000;
Thummel et al., 2000; Kim et al., 2003), fasting/malnutrition (Shi et al., 1982; Price et al., 1987; Price and Jollow, 1988; Price and Jollow, 1989)).
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alter different components of a system, such as chronic
use of APAP and consumption of alcohol, it might be
reasonable to assume that the effects could be com-
bined. However, when processes alter the workings of
the same reactions, especially if they are conflicting in-
fluences (like chronic APAP use and fasting), it would
be unwise to make assumptions about the outcome.
For this reason, in this paper we have simulated drug
metabolism in chronic APAP users who consume ex-
cessive amounts of alcohol but refrained from simulat-
ing APAP metabolism in any other combinatorial way,
such as malnourished individuals who use the drug on
a regular basis.
Results and discussion
Famous Swiss-German alchemist Philippus Aureolus
Paracelsus wrote: “All things are poison and not with-
out poison; only the dose makes a thing not a poison”
(Krieger, 2001). This statement is particularly apt for
acetaminophen. While small quantities of APAP relieve
suffering, relatively slight excess intake by some patients
can result in acute liver damage. Significant overdose of
APAP causes mitochondrial dysfunction and centrilobular
necrosis in the liver and can be lethal (e.g., (McJunkin et al.,
1976; Nogen and Bremner, 1978; Price et al., 1991)).
Many drugs are toxic due to production of chemically
reactive metabolites that deleteriously alter the normal
biochemistry of a patient. The amount of damage that
these compounds cause depends on their concentration
and metabolic half-life. Some of the toxic byproducts of
drug metabolism are so short-lived that they never exit
the organs in which they are formed. On the other hand,
chemical change of others can be slow enough that they
enter the systemic circulation and are transported to other
organs. NAPQI, the toxic byproduct of APAP metabolism,
is one of the former and does not leave the liver.
NAPQI can bind to sulfhydryl groups of cellular proteins
and cause oxidative stress. Experiments have shown
that harmful covalent binding of NAPQI to proteins is
preceded by significant depletion of glutathione in the
liver (Mitchell et al., 1973; Davis et al., 1974) because
low doses of NAPQI are rapidly detoxified by glutathione
through conversion of NAPQI to glutathionyl acetamino-
phen (Mitchell et al., 1973; Mitchell et al., 1974). Thus,as long as hepatic concentration of GSH remain sufficiently
high, liver proteins are not altered (Jollow et al., 1973;
Mitchell et al., 1973), and hepatotoxicity can be averted
through replenishment of GSH and introduction of comple-
mentary antioxidants (e.g., treatment with N-acetyl-cysteine
(Peterson and Rumack, 1977; Prescott et al., 1977)).
A number of factors affect the rate of APAP and NAPQI
metabolism in a patient (Larson, 2007). The three that have
the most widespread impact on the public are: chronic use
of APAP, fasting, and alcohol consumption. In cases where
patients have exhibited combinations (e.g. (Whitcomb and
Block, 1994)) of above noted conditions, the effects of each
factor have not been quantified. This ambiguity about the
quantitative effects of each condition has resulted in differ-
ing postulates about the safety of APAP and the primary
culprit for predisposing some patients to show signs of
liver damage following moderate overdoses (4–10 g/day)
or even uptake of therapeutic doses (4 g/day) (Whitcomb
and Block, 1994; Slattery et al., 1996; Prescott, 2000).
Overall, any systemic perturbation that results in reduced
glutathione concentration, induction of CYP enzymes,
or reduced rates of sulfation or glucuronidation should
be considered for increasing a patient’s susceptibility to
hepatotoxicity. Given the uncertainty associated with
completeness of patient histories in clinical records and
the difficulty of parsing the collected information to
quantify the deleterious effects of various daily habits,
in silico pharmacological analysis is the sole means by
which we can use the available biochemical data to gain
a quantitative understanding of kinetics of hepatotox-
icity in compromised patients. To this end, we devel-
oped a detailed PBPK model of APAP metabolism in
humans and used it to simulate generation and detoxifi-
cation of NAPQI for a number of prevalent scenarios.
To date a number of other pharmacokinetic models of
APAP and GSH metabolisms have been developed
(Chen and Gillette, 1988; Tone et al., 1990; Srinivasan et al.,
1994; Chiba and Pang, 1995; Ben-Shachar et al., 2012;
Remien et al., 2012; Westerhout et al., 2012) and signifi-
cantly contributed to our understanding of the dynam-
ics of APAP induced hepatotoxicity. However, each of
these studies focused on a specific portion of the meta-
bolic process and did not simulate and examine the
combined effects of the noted determining factors on
the important aspects of drug metabolism.
Figure 3 Predicted and measured acetaminophen plasma
concentrations. The results are for three days of multiple dosing
with 1 g every 6 hours (Gelotte et al., 2007) (●)).
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In order to ensure that the incorporated kinetic parame-
ters are correct, the model’s predictions were compared
against clinical measurements (see Figures 2 and 3). The
model predictions strongly agree with two sets of measured
results (Rawlins et al., 1977; Kennedy and Van Rij, 2006) for
the short period after introduction of APAP (Figure 2) and
for longer time periods associated with chronic use of
APAP (Gelotte et al., 2007) (Figure 3).
Next, depletion of GSH concentrations in the liver
following uptake of different doses of APAP were examined
(see Figure 4). As noted in the methods section, the re-
generation mechanism of GSH in the model has been
parameterized so that intake of a single 15 g dose of
APAP (generally accepted upper limit of APAP prior
to generation of hepatotoxicity (Mitchell et al., 1974;
Whitcomb and Block, 1994; Rumack, 2002)) depletes the
liver GSH level by approximately 70%, and thus greater
doses would dip GSH level below 30% of normal level and
initiate liver damage.
Chronic APAP use
Acetaminophen should be used cautiously when taken
on a chronic basis because even for some patients
without risks, APAP may be hepatotoxic at therapeutic
doses (Bolesta and Haber, 2002). Statistical analyses
have shown that the odds of developing ALF, following
use of therapeutic doses of APAP, are extremely small
(0.4 per million adults over the age of 15 per year)
(Sabaté et al., 2011). The PBPK model was used to deter-
mine if the recorded kinetic characteristics of APAP meta-
bolic pathways can account for this rare phenomenon.
The model predicts that under normal conditions, con-
tinual uptake of 1 g of APAP every 6 hours results in
approximately a 15% reduction in steady state levels of
liver GSH (Figure 5). This result agrees with recorded
observations (Nuttall et al., 2003). This level of GSH
should sufficiently prevent hepatotoxicity in normalFigure 2 Predicted and measured acetaminophen plasma
concentrations. The results are for following a single intravenous
bolus injection of a 1 g dose. The measured values are from
(Rawlins et al., 1977) (■) and (Kennedy and Van Rij, 2006) (●).patients. Furthermore, as can be seen in Figure 5, the
simulations of GSH concentration, following continual
uptake of 1, 2 and 5 g every 6 hours show that none of
these regimens should result in a reduction of GSH
levels bellow 30% of the normal steady state values.
Hence, it can be deduced that the reported patients
(who based on their collected history are not supposed
to be at risk of APAP poisoning) must have some unique
physiological characteristic that increases their susceptibil-
ity to oxidative damage. One possibility could be that for
these individuals routes of APAP metabolism are not
changed following chronic uptake of 1–2 g doses of
APAP (Gelotte et al., 2007). Based on measured single
dose pharmacokinetics of APAP metabolism, the sulfa-
tion capacity of the liver sulfatransferases could be sat-
urated and more of the drug would be shunted toward
NAPQI production, specially following continual in-
gestion of high doses APAP. Clinical studies of healthy
patients ingesting multiple doses of APAP have shown
that the serum sulfate concentration can drop signifi-
cantly (Hendrix-Treacy et al., 1986). However, recent
experimental examinations have shown that at higher
doses, chronic uptake of APAP results in an approxi-
mately 23% increase in the clearance rate of APAP-G
(Gelotte et al., 2007).Figure 4 Predicted glutathione depletion following single dose
ingestions of 4 (black), 10 (red), and 15 (blue) g of APAP. The
gray dashed line marks the minimum level of GSH that is necessary
to prevent intrahepatic covalent binding by NAPQI.
Figure 5 Predicted liver glutathione concentration following
chronic ingestion of APAP at 3 different daily doses (1 g/6 hours
(black), 2 g/6 hours (blue), and 5 g/6 hours (red)). Solid lines
represent simulations with induction of APAP glucuronidation and
reduction of APAP sulfation (Gelotte et al., 2007). Dashed curves are for
simulations that do not incorporate the observed changes. The gray
dashed line marks the minimum level of GSH that is necessary to
prevent intrahepatic covalent binding by NAPQI.
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trations of GSH with and without alterations in APAP
metabolism. Chronic uptake of APAP clearly behaves
like hormesis. The increased glucuronidation/reduced
sulfation of APAP overall has a protective effect. For
example, the area under the curves from Figure 5 shows
that following uptake of 1, 2 and 5 g of APAP every six
hours for 5 days, diversion of APAP metabolism to glucuro-
nidation reduces the need for GSH detoxification by
about 1, 10, and nearly 50%, respectively. While induction
of UDP-glucuronosyltransferase appears to have a signifi-
cant beneficial effect on diverting APAP away from NAPQI
production, particularly at higher doses, the loss of the
1% improvement cannot explain the observed toxicity
following therapeutic doses of APAP.
Other possibilities for the observed phenomenon can
be induction of NAPQI- producing CYPs, reduced
rates of hepatic GSH generation, or a combination of
both. According to model simulations, increasing the rate
of CYPs more than 30 times will result in hepatotoxicity
following periodic uptake of 1 g of APAP every 6 hours.
Such a drastic increase in CYP activity seems highly un-
likely, and the mechanism of induction is unclear. One pos-
sibility could be that like the behavior observed following
interaction between CYPs and alcohol, acetone, or isoniazid
(Ryan et al., 1986; Song et al., 1987), over an extended
period of time, a compound that has not been considered
as a part of a patient’s history slowly induces enzymes such
as CYP2E1 through ligand stabilization. Then, a relatively
rapid drop in concentration of that compound would result
in much greater APAP oxidation. To date, a compound
that could so drastically induce the activity of CYPs has not
been found.




) by only a factor 5 would makechronic ingestion of 1 g of APAP every 6 hours toxic after
about 1 day. This metabolic change seems a lot more plaus-
ible as a cause for the observed phenomenon where thera-
peutic usage of APAP could lead to sever hepatotoxicity.
Fasting or poor nutrition is a prime candidate for why a
person might present reduced GSH production capabilities.
A number of other studies have also suggested that re-
duced levels of GSH, resulting from poor nutrition, could
result in elevated risk of APAP induced hepatotoxicity
(e.g., (Whitcomb and Block, 1994; Prescott, 2000)).
Some herbal remedies and natural products have been
recommended as protection against hepatotoxicity through
scavenging of reactive oxidative species and disruption of
cell death signaling mechanisms (e.g.,Oz et al., 2005; Chen
et al., 2009; Wang et al., 2010; Galal et al., 2012)); however,
depending on a variety of factors (like time of ingestion in
relation to APAP uptake (Salminen et al., 2012)), the results
might vary, and the treatment might actually potentiate
hepatotoxicity. Accounting for such heretofore ignored
factors could lead to answers about how therapeutic
doses of APAP could lead to ALF.
Chronic alcoholism
Activity of many CYPs can be altered in the presence of
some drugs and other common biochemical substrates
(Hewitt et al., 2007). Analysis of interaction of ethanol with
APAP is very complicated, and the resulting conclusions
can be controversial (Slattery et al., 1996; Prescott, 2000).
For example, in animals, concurrent ingestion of ethanol
with APAP actually protects the patient against hepatotox-
icity even if prior chronic intake of alcohol has induced the
liver’s CYP activities (Sato et al., 1981; Altomare et al.,
1984; Thummel et al., 1989). If one assumes that similar
mechanisms govern alcohol-APAP interaction in humans
as in animals, then alcohol could decrease, increase, or
have no effect on the toxicity of APAP, depending on the
timing and duration of alcohol consumption.
The deleterious effects of alcohol on maintaining the
normal GSH concentrations in hepatocytes are twofold.
First, chronic ingestion of alcohol impairs transport of
GSH from hepatocyte cytosol to mitochondria while in-
creasing efflux of GSH from the liver (Fernandez-Checa
et al., 1989; Choi et al., 2000). There is some controversy
about the identity of the causative agent of GSH deple-
tion following alcohol consumption. Some studies have
shown that ethanol, rather than its metabolic products,
alters in vivo regulatory events and causes the reduction
of liver GSH (Speisky et al., 1988). On the other hand,
others have shown that although proximate metabolites of
ethanol (acetaldehyde and acetate) by themselves appear
to have limited effect on GSH levels, hybrid aldehyde
adducts (e.g., malondialdehyde-acetaldehyde (Tuma, 2002))
and their role in enhancing lipid peroxidation (Hartley and
Petersen, 1997) can deplete GSH.
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metabolism of ethanol (Lieber and DeCarli, 1970; Koop
et al., 1982) and is induced by the presence of this
compound (Koop and Tierney, 1990), principally due
to a post-transcriptional mechanism where presence of
the substrate stabilizes the enzyme from degradation
(Song et al., 1986). Alcohol acts as a competitive inhibitor
of the APAP oxidation reaction and while present in the
body protects the liver against production of NAPQI. How-
ever, after clearance of alcohol from the system, greater
availability of CYP2E1 increases (up by a factor of 2) the
rate of conversion of APAP to toxic NAPQI molecules
(Thummel et al., 2000).
Figure 6 shows the transient hepatic GSH levels following
continual uptake of therapeutic doses of APAP after a
period of extreme binge drinking (200 hours of continual
blood alcohol level of 3 g/L). CYP induction only increases
the need for GSH detoxification by approximately 7% more
than that in a non-alcoholic person.
Given the short half life of deleterious effects of alcohol
consumption on hepatic GSH levels (~12 hours (Choi et al.,
2000)), the most dangerous period for a person drinking
and chronically taking APAP would be the first 12–18 hours
after drinking has stopped. During this period, if alcohol
consumption reduces the hepatic steady state concentration
of GSH and the rate of its regeneration to half the normal
values, then consecutive uptake of supra-therapeutic doses
of APAP can be toxic. Interestingly, the model predicts that
as long as the GSH production capacity of liver return to
normal within a reasonable period of time (24–36 hours),
and the detoxifying capacity of the liver is not challenged
by other toxins, then chronic use of therapeutic doses of
APAP should not result in liver injury.Figure 6 Predicted liver glutathione concentrations following
chronic ingestion of therapeutic doses of APAP (1 g/6 hours).
The black line shows GSH concentration in a normal person. The
blue line shows GSH concentration following a period of binge
drinking accounting only for the 2.14 times increase of the APAP
oxidation pathway (Thummel et al., 2000). The red line shows the
model-predicted liver GSH concentration when it accounts for both
CYP induction and 50% reduction in steady state concentration of
GSH and its regeneration rate. The gray dashed line marks the
minimum level of GSH that is necessary to prevent intrahepatic
covalent binding by NAPQI.This result is in strong agreement with some of the
published arguments that have reasoned that CYP in-
duction cannot form the primary basis for the strong
link between APAP induced hepatotoxicity and use of
alcohol (Prescott, 2000). The main reason for increased
cases of APAP-induced hepatotoxicity is reduced availabil-
ity of GSH. While depletion of hepatic GSH is a rare mode
of toxicity for drugs (examples in (Kostrubsky et al., 2007;
Dykens et al., 2008)), it is common for a variety of toxicants
such as carbon tetrachloride (Jaeschke et al., 2013). It can
also occur in individuals consuming certain herbal medica-
tions (Senadhi et al., 2012) like pennyroyal oil (Chitturi and
Farrell, 2000). Accordingly, one can argue that APAP is
not unique in its toxicity to alcoholics and that for these
individuals exposure to any compound that would be me-
tabolized in the liver to produce reactive oxidative species
could result in hepatotoxicity.
Fasting and malnutrition
Malnutrition is one of the primary instigators of hepatotox-
icity following moderate (4–10 g/day) overdose of APAP
(Whitcomb and Block, 1994). The PBPK model predictions
agree with these observations. Figure 7 shows the model-
predicted hepatic GSH levels following ingestion of 4 g of
APAP. The results indicate that the combined effect of
reduced hepatic GSH levels and its rate of regeneration
along with augmented enzymatic activities could make a
single dose uptake of 4 g of APAP harmful. When the
outcomes resulting from changes to enzyme activities
are compared to those associated with reduced GSH levels,
the deleterious effects seem to be of the same magnitude
(Figure 7, green and blue lines respectively). This result is
significant because it indicates that treatments that only re-
supply the liver with antioxidants might not be enough to
significantly reduce the risk of hepatotoxicity.Figure 7 Predicted liver glutathione levels following ingestion
of a 4 g dose of APAP. The black line represents metabolism in a
healthy well-fed person. The red line represents metabolism in a
malnourished individual. The blue line represents GSH levels if only the
GSH levels and its regeneration rates are altered as a result of malnutri-
tion. The green line represents the outcome if fasting only change the
activity of APAP metabolizing enzymes. The gray dashed line marks
the minimum level of GSH that is necessary to
prevent intrahepatic covalent binding by NAPQI.
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The number of ALF cases in United States attributed to
acetaminophen have been continually rising (Larson et al.,
2005; Nourjah et al., 2006), and there has been a lot of de-
bate about safety of this popular drug. A number of differ-
ent factors have been suggested as the primary cause of
hepatotoxicity in patients. In this study, we conducted a
quantitative examination of the effects of chronic APAP
use, alcohol consumption, and malnutrition on increasing
the risks of liver damage. The results of our simulations
show that there is a hormesis-like protective behavior
following chronic consumption of APAP. The shunting
of metabolism to the glucuronidation pathway reduces
production of toxic byproducts at higher doses, and
this could have a significant protective effect.
Our simulations show that alcohol drinkers who are
chronic acetaminophen users have an increased risk of
liver damage particularly within the first day following
an episode of binge drinking. However, these individuals
are at risk from any compound that could be activated to
act as an oxidizing agent, and therefore APAP is not unique
in its toxicity.
Finally, our analysis of APAP metabolism in fasting
patients show that they are at a much greater risk of
hepatotoxicity, resulting from a mild overdose (4–10 g),
than well-fed individuals. For these individuals, a combin-
ation of factors, including shunting of drug metabolism to
oxidative pathways and reduced rate of glutathione metab-
olism, exacerbate the problem and complicate the treat-
ment choices since focusing on only one of the above
causes might not fully mitigate the problem.
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